PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence

BACKGROUND: Immune checkpoint inhibitors (ICIs) have provided new therapeutic options for non‐small cell lung cancer(NSCLC) patients. However, due to concerning increases in immune‐related adverse events, clinical trials usually exclude patients with special issues such as viral hepatitis, tuberculo...

Descripción completa

Detalles Bibliográficos
Autores principales: Byeon, Seonggyu, Cho, Jang Ho, Jung, Hyun Ae, Sun, Jong‐Mu, Lee, Se‐Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung‐Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131857/
https://www.ncbi.nlm.nih.gov/pubmed/32027780
http://dx.doi.org/10.1002/cam4.2868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131857/
https://www.ncbi.nlm.nih.gov/pubmed/32027780
http://dx.doi.org/10.1002/cam4.2868

Ejemplares similares